Silver Spring, Maryland–(ENEWSPF)–October 23, 2015. The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who previously received chemotherapy that contained anthracycline.
According to the National Cancer Institute, STS is a disease in which cancer cells form in the soft tissues of…
